The Scientist THLD with continued high short interest. Of all the stocks to short, this is one of the worst. Solid data. Potential to go up 10x quickly
8/24/12
Reply
(3)
•!Report Abuse
View all 3 replies
HJStebbins: i like where your heads at ...i would like to see the chart mirror that of PCYC
8/24/12
•!Report Abuse
The Scientist: Th-302 could be the breakthru drug that oncologists have been looking for. By targeting hypoxic niche, kills CSCs that promotes recurrence
8/27/12
•!Report Abuse
The Scientist: Hypoxic CSCs r the 'untouchables' in oncology. Must b killed, but cannot get to them.